Status:

COMPLETED

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

Lead Sponsor:

Alachua Government Services, Inc.

Conditions:

Influenza

Eligibility:

All Genders

16+ years

Phase:

PHASE2

PHASE3

Brief Summary

The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.

Eligibility Criteria

Inclusion

  • Male and female subjects will be eligible for participation in this study if they:
  • are \>= 18 and \<= 60 years old (for Stratum A only);
  • are \> 60 years old (for Stratum B only);
  • are in a physical condition such that the physician would have no reservations vaccinating with an influenza vaccine outside the scope of a clinical trial;
  • will reliably keep a daily record of symptoms;
  • understand the nature of the study, agree to its provisions, and give written informed consent;
  • if female and capable of bearing children - show a negative pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study.

Exclusion

  • Male and female subjects will be excluded from participation in this study if they:
  • have received any influenza vaccine for the 2002/2003 season and/or for the 2003/2004 season;
  • suffer from any kind of immunodeficiency;
  • suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions;
  • have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré, multiple sclerosis);
  • have received a blood transfusion or immunoglobulins within one month of study entry;
  • have a history of any vaccine-related contraindicating event (e.g. anaphylaxis);
  • have a rash or dermatological condition which may interfere with injection site reaction rating;
  • have a known or suspected problem with drug or alcohol abuse;
  • are unable to lead an independent life either physically or mentally;
  • had administration of an investigational drug within six weeks prior to the study start;
  • are concurrently participating in a clinical trial;
  • are pregnant or lactating.

Key Trial Info

Start Date :

December 1 2003

Trial Type :

INTERVENTIONAL

End Date :

July 1 2004

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00161837

Start Date

December 1 2003

End Date

July 1 2004

Last Update

October 9 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PANTAMED Sp.z o.o.

Olsztyn, Poland, PL-10-461